Cover Image

High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting

Show other versions (1)

High-dose (HD) chemotherapy with melphalan and autologous blood stem cell transplantation (ABSCT) for treatment of symptomatic multiple myeloma (MM) on an outpatient basis has been well established in the USA and Canada, whereas in Germany and Western Europe an inpatient setting is the current stand...

Full description

Saved in:
Bibliographic Details
Main Authors: Kriegsmann, Katharina (Author) , Sauer, Sandra (Author) , Bruckner, Thomas (Author) , Egerer, Gerlinde (Author) , Goldschmidt, Hartmut (Author) , Hillengaß, Jens (Author) , Schmier, Johann-Wilhelm Adam (Author) , Shah, Sofia (Author) , Witzens-Harig, Mathias (Author) , Ho, Anthony Dick (Author) , Wuchter, Patrick (Author)
Format: Article (Journal)
Language:English
Published: 22 February 2017
In: BMC cancer
Year: 2017, Volume: 17
ISSN:1471-2407
DOI:10.1186/s12885-017-3137-4
Online Access:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1186/s12885-017-3137-4
Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12885-017-3137-4
Get full text
Author Notes:Katharina Lisenko, Sandra Sauer, Thomas Bruckner, Gerlinde Egerer, Hartmut Goldschmidt, Jens Hillengass, Johann W. Schmier, Sofia Shah, Mathias Witzens-Harig, Anthony D. Ho, Patrick Wuchter
Description
Summary:High-dose (HD) chemotherapy with melphalan and autologous blood stem cell transplantation (ABSCT) for treatment of symptomatic multiple myeloma (MM) on an outpatient basis has been well established in the USA and Canada, whereas in Germany and Western Europe an inpatient setting is the current standard. We report on a German single-centre program to offer the procedure on an outpatient basis to selected patients.
Item Description:Gesehen am 10.04.2018
Physical Description:Online Resource
ISSN:1471-2407
DOI:10.1186/s12885-017-3137-4

Similar Items